Biopharma · FDA Approvals · Stock
LABT Lakewood-Amedex
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The compan…
Assets on file: Bisphosphocin Nu-8, Nu-3, Nu-3
Catalyst calendar
Dated catalysts for LABT, including recently decided ones.
Recent first-hand events
Every first-hand event for LABT, newest first.
Lakewood-Amedex Presents Nu-3 Data at IDWeek 2026
Lakewood-Amedex presented preclinical data on Nu-3 showing rapid bactericidal activity against resistant pathogens and low resistance potential. The data support its development as a topical treatment for infected diabetic foot ulcers.
Lakewood-Amedex announced positive preclinical results showing intravesical Bisphosphocin Nu-8 achieved up to 97% inhibition of E. coli growth in a rodent UTI model versus no effect in vehicle control. This is the first reported efficacy data for the compound in urinary tract and pulmonary infection indications.
Lakewood-Amedex to Present Nu-3 at ThinkEquity and IDWeek in October 2026
Lakewood-Amedex announced CEO participation and a poster presentation of Nu-3 preclinical data at IDWeek. The company will also attend the Maxim Growth Summit and ThinkEquity Conference.
Lakewood-Amedex Announces Positive Nu-3 Data in Infected Diabetic Foot Ulcers
The company reported positive data for its lead candidate Nu-3 against recent clinical isolates from infected diabetic foot ulcers. Nu-3 is a topically formulated Bisphosphocin designed to rapidly kill microbes while reducing antimicrobial resistance risk.
Lakewood-Amedex doses first patient in Phase 2a trial of Nu-3 for infected diabetic foot ulcers
Lakewood-Amedex Biotherapeutics has initiated dosing in its Phase 2a clinical trial of Nu-3 (a Bisphosphocin antimicrobial) for infected diabetic foot ulcers. This marks the start of the study, with topline data now expected in Q1 2027.
Lakewood-Amedex (LABT) Receives IRB Approval to Start Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers
Lakewood-Amedex obtained central and site IRB approvals and confirmed clinical trial site readiness to initiate its Phase 2a trial of topical Nu-3 gel. The study will evaluate safety and efficacy in patients with mildly infected diabetic foot ulcers, building on prior preclinical and exploratory data.
Peers by market cap
Companies in the same sector closest to LABT in market value.
SCNIScinai ImmunotherapeuticsMarket cap $638.2K
DCOYDecoy TherapeuticsMarket cap $701.0K · 2 tracked drugs
LNAILunai BioworksMarket cap $747.2K
JAGXJaguar HealthMarket cap $842.5K · 1 tracked drug · 3 upcoming catalysts
MTNBMatinas BioPharmaMarket cap $1.5M
OGENOragenicsMarket cap $1.7M · 1 tracked drug
KAPAKairos PharmaMarket cap $1.8M · 2 tracked drugs